# Eyenovia Announces Financial Results and Strategic Developments for Q1 2025

“In addition to these strategic initiatives, we undertook crucial measures over the past several months to cut expenses, optimize our balance sheet, and extend our cash runway. A key highlight is our debt restructuring agreement with Avenue Capital, which remains supportive as we finalize a merger agreement with Betaliq. We anticipate that this merger could lead to significant value inflection points within the year,” stated Mr. Rowe.

First Quarter 2025 Financial Review

For Q1 2025, Eyenovia reported a net loss of $3.5 million, translating to $1.59 per share. This marks an improvement from a net loss of $10.9 million, or $18.75 per share, for the same quarter in 2024.

Research and development expenses stood at $0.7 million for Q1 2025, a significant decrease of 85% from $4.4 million in Q1 2024.

General and administrative expenses were $2.4 million for the first quarter of 2025, down 35% from $3.6 million reported in Q1 2024.

Total operating expenses for the quarter were $3.0 million, down 70% compared to $10.1 million in Q1 2024.

As of March 31, 2025, Eyenovia had unrestricted cash and cash equivalents totaling $3.9 million, an increase from $2.1 million in unrestricted and restricted cash as of December 31, 2024.

About Eyenovia, Inc.

Eyenovia, Inc. is an ophthalmic technology firm focused on developing advanced products through its proprietary Optejet topical ophthalmic medication dispensing platform. This platform proves beneficial in treating chronic front-of-the-eye diseases, providing ease of use, enhanced safety, and patient compliance compared to standard eye drops. Eyenovia’s current commercial offerings include clobetasol propionate ophthalmic suspension, 0.05%, aimed at reducing post-surgical pain and inflammation, as well as Mydcombi

^®

for mydriasis. Further details can be found at Eyenovia.com.

Forward-Looking Statements

All statements beyond historical facts in this release are forward-looking in nature. These include, but are not limited to, intentions, beliefs, expectations, and projections regarding the potential transaction with Betaliq, future activities, and the estimated market opportunities for our platform technology. These statements are based on current expectations and management assumptions. They are not guarantees of future performance, as various risks and uncertainties could lead to actual outcomes differing significantly from those projected.

Moreover, these forecasts may be influenced by several factors, including risks associated with the proposed deal with Betaliq, challenges faced during clinical trials, market acceptance of our products, and our ability to secure additional funding and meet debt obligations. Eyenovia does not commit to updating these forward-looking statements unless required by applicable securities laws.

Eyenovia Contact:

Eyenovia, Inc.

Norbert Lowe

[email protected]

Eyenovia Investor Contact:

Eric Ribner

LifeSci Advisors, LLC

[email protected]

(646) 751-4363

“`html

Company Financials: Assets Overview for 2024 and 2025

EYENOVIA, INC.
Condensed Balance Sheets
				March 31,				December 31,

2025				2024
Assets
Current Assets
	Cash and cash equivalents			$	3,934,966			$	2,121,463
	License fee and expense reimbursements receivable				25,787				24,827
	Security deposits, current				14,968				14,968
	Prepaid expenses and other current assets				1,183,262				605,941

“““html

Total Current Assets and Financial Liabilities Overview

Total Current Assets		5,158,983			2,767,199
Security deposits, non-current					182,200		182,200
Operating lease right-of-use asset					642,770		718,360
		Total Assets		$	5,983,953		$	3,667,759
Liabilities and Stockholders’ Deficiency
Current Liabilities:
Accounts payable			$	1,199,961		$

“`# Current Liabilities Breakdown Reveals Financial Health Insights

—

### Overview of Current Liabilities

The current liabilities of the organization reveal significant financial obligations that warrant examination. Below is a detailed breakdown of the current liabilities reported.

—

### Key Financial Figures

– **Total Accrued Compensation**
– Amount: **$2,199,768**

– **Accrued Compensation Breakdown**
– Amount for current period: **$109,934**
– Previous period amount: **$144,161**

—

### Accrued Expenses and Other Current Liabilities

– **Current Amount**: **$3,241,554**
– **Previous Amount**: **$3,178,513**

—

### Operating Lease Liabilities

– **Operating Lease Liabilities – Current Portion**
– Current Amount: **$542,561**
– Previous Amount: **$575,163**

—

### Notes Payable

– **Notes Payable – Current Portion**
– Current Amount: **$729,999**
– Relevant Debt Discount: **$56,954**

—

### Convertible Notes Payable

– **Convertible Notes Payable – Current Portion**
– Current Amount: **$9,276,275**
– Relevant Debt Discount: **$723,725**

—

### Summary of Current Liabilities

– **Total Current Liabilities**
– Current Period Amount: **$15,100,284**
– Previous Period Amount: **$16,046,207**

—

This breakdown of current liabilities offers critical insights into the company’s financial position, reflecting obligations that play a vital role in assessing liquidity and financial health.# Financial Overview: Key Liabilities and Stockholder Information

**Operating Lease Liabilities**
The non-current portion of operating lease liabilities stands at **$597,670** as of March 31, 2025. This reflects a significant change compared to **$717,504** noted on December 31, 2024.

**Total Liabilities**
Total liabilities are reported at **$15,697,954** for March 31, 2025, compared to **$16,763,711** for the previous year. This indicates a reduction in financial obligations.

**Stockholders’ Deficiency**
Under the stockholders’ deficiency section, the preferred stock has a par value of **$0.0001** with **6,000,000 shares authorized**. Notably, **0 shares** of preferred stock have been issued as of March 31, 2025, and December 31, 2024.

Common stock, also with a par value of **$0.0001** and **300,000,000 shares authorized**, reports **2,830,546 shares** issued and outstanding as of March 31, 2025. This is an increase from **1,506,369 shares** noted on December 31, 2024.

**Additional Paid-in Capital**
In relation to additional paid-in capital, further details will follow as this financial narrative unfolds. The performance metrics suggest careful financial management and adjustment responses to market conditions over the reported periods.# EYENOVIA, INC. Reports Financial Overview: Key Figures and Insights

	189,079,241				182,213,889
	Accumulated deficit				(198,793,525	)			(195,309,992	)
		Total Stockholders’ Deficiency			(9,714,001	)			(13,095,952	)
		Total Liabilities and Stockholders’ Deficiency		$	5,983,953			$	3,667,759

# Financial Overview for the First Quarter Ending March 31

## Summary of Key Financial Figures

In this report, we present vital financial data for the quarter ending March 31, including operating income, revenue, and expenses.

### Revenue and Gross Profit

For **2025**, the revenue reached **$14,720 million**, marking a steady increase compared to the previous year’s $4,993 million. Cost of revenue, however, accounted for a reduction, with costs reported as **($48 million)** for **2025** and **($203,027 million)** for **2024**.

Consequently, the gross profit presented a robust figure of **$14,672 million** for the current year compared to a significant loss of **($198,034 million)** in the prior year.

### Operating Expenses

Operating expenses remain a crucial aspect of our financial health. Detailed breakdowns will follow to illustrate trends and operational efficiencies or challenges facing the company.

This structured overview includes all significant financial figures, demonstrating a comprehensive look at the company’s performance in the first quarter. Further details on operating expenses and operating income will be disclosed in subsequent sections.# Financial Overview Reveals Key Insights into Company Operations

## Operating Expenses Breakdown

### Research and Development Costs
– **Amount**: $673,043

### Selling, General, and Administrative Expenses
– **Amount**: $2,372,322

### Reacquisition of License Rights
– **Amount**: $2,000,000

### Total Operating Expenses
– **Amount**: $10,068,790

## Loss From Operations
– **Current Period**: $(3,030,693)
– **Previous Period**: $(10,266,824)

## Other Income and Expenses

### Other (Expense) Income, Net
*(Further details would follow here.)*

—

This overview provides a clear financial picture of operating expenses, highlighting research, selling, and license reacquisition costs. The loss from operations shows a significant improvement when comparing the current and previous periods. Further details on other income and expenses will be necessary for a complete analysis.# Financial Report Reveals Significant Loss Amidst Interest Challenges

### Overview of Financial Performance

In a recent report, the company experienced considerable financial losses, indicating ongoing challenges related to interest expenses.

### Debt Extinguishment Gains

The company reported a substantial gain on debt extinguishment, amounting to **$89,623**. However, this figure is overshadowed by the broader financial picture.

### Interest Expenses

The impact of interest expenses is significant. The company recorded interest expenses of **$(581,499)** and **$(678,658)** in comparative terms. This increase in interest costs continues to strain financial performance.

### Interest Income Insights

On the brighter side, interest income was reported at **$35,349** and **$120,939** for the periods assessed. While this brings some relief, it is insufficient to counterbalance the high expenses incurred.

### Total Other Expenses

The total other expenses reached **$(452,840)**, further compounding the financial strain, with an aggregate figure of **$(655,277)** for all expenses reported.

### Concluding Financial Loss

Ultimately, the report culminates in a net loss of **$(3,483,533)**. This significant figure underscores the financial difficulties faced by the company, driven largely by mounting interest expenses and overall operational costs. The management will need to devise strategies to enhance financial stability moving forward.# Financial Update: Key Metrics Reflect Company Performance

## Net Loss Per Share

The company reported a net loss per share, both basic and diluted, of **$(1.59)**. This figure is notable when compared to the previous year’s loss of **$(18.75)** per share.

## Shares Outstanding

Shares outstanding for the company stood at **2,188,938** for basic shares and **582,584** for diluted shares. These numbers provide insight into the company’s equity structure as it continues to navigate market challenges.

## Conclusion

In summary, the latest financial metrics illustrate improvements in net loss per share, suggesting potential positive shifts in the company’s operational effectiveness. The substantial difference from the previous year indicates promising directions, though more context may be required for a comprehensive evaluation.

—
The article was previously featured in Quiver News. The views presented are those of the author and do not necessarily reflect the stance of Nasdaq, Inc.

EYENOVIA, INC.
Condensed Statements of Operations
(unaudited)